Dr. Lal PathLabs Limited records revenue growth of 12% in Q1FY2017-18

2024-04-29 11:13:06 Business

739

New Delhi, India, Aug 7, 2017? Dr. Lal Path Labs Limited (referred to as the ?Company?; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2017

Consolidated Performance Highlights: Q1FY2017-18 vs. Q1FY2016-17

Revenue growth: 12% Normalised EBITDA growth: 11%, Normalised EBITDA margin maintained at 27.3%

? Operating Revenue increased by 11.9% in Q1 to Rs. 2493 million vs Rs 2228 million in the previous year same quarter. Underlying volume growth is 9.1% during the quarter.

? Normalised EBITDA increased by 11% in Q1FY18 to Rs.680 million from Rs 613 million in the same quarter last year, after adjusting for ESOP and other stock based compensation costs.

? EBITDA Margin was 27.3% for Q1 FY18 vs 27.5% in Q1 FY17. Consequently PBT was higher by 9.2% in Q1

? Profit after Tax in Q1 has improved by 11.7% to Rs. 446 million in Q1FY18 from Rs 399 million in Q1 FY17
About Dr. Lal PathLabs Limited

Dr. Lal Path Labs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal Path Labs has built a national, ?hub and spoke? network that includes its National Reference Laboratory in New Delhi, 188 other clinical laboratories, 1,759 patient service centers and 5,021 pickup points as of March 31, 2017. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.